Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
IRVINE, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the “Company”) is pleased to announce that the Company’s recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the Denmark authorities, and the formal review process has now started. The trademarked name for the new product is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted at the beginning of December 2022. The Company will continue to provide further information, including other expected submissions, when the information becomes available.